secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001104659-23-088823
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q2 net loss $8.4M, revenue $17.2M; DFD-29 Phase 3 positive, NDA submission H2 2023
--------------------------------------------------------------------------------

- Q2 2023 net revenues $17.2M, down 6% YoY but up 41% QoQ; core product revenue grew 19% YoY to $15.6M (92% of total).
- GAAP net loss $8.4M ($0.46/sh) vs $7.5M loss ($0.43/sh) in Q2 2022; adjusted EBITDA improved to -$0.6M from -$2.6M.
- DFD-29 Phase 3 trials met co-primary and all secondary endpoints, superior to placebo and Oracea; NDA submission planned H2 2023.
- Non-cash impairment of Ximino intangible asset of $3.1M; SG&A down 20% to $12.1M from cost reduction initiatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923088823/0001104659-23-088823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923088823/tm2323104d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer